OnCo
termsTerm

ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)

aka ABVD, A+AVD, AVD, BV-AVD, brentuximab vedotin-AVD, BEACOPP, escalated BEACOPP, eBEACOPP, BrECADD, N-AVD, nivolumab-AVD, Stanford V

The chemotherapy recipes that cure most Hodgkin lymphoma: ABVD (four drugs, the long-standing standard), the more intensive German BEACOPP, and newer versions that replace bleomycin with brentuximab vedotin (A+AVD) or add nivolumab (N-AVD).

ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) cures 70-80% of advanced disease with interim PET guiding bleomycin omission (RATHL); escalated BEACOPP raises progression-free survival to about 90% at the cost of infertility and secondary cancers. A+AVD improved survival over ABVD (ECHELON-1), N-AVD beat A+AVD on progression-free survival in SWOG S1826 (2024), and BrECADD matched escalated BEACOPP with less toxicity (HD21). Late effects of these curative regimens (cardiac, pulmonary, breast cancer after radiotherapy) drive the continuing effort to de-escalate.

Category
Treatment jargon

Connected

11top

Pages like this

not linked directly; found by shared links

cancers

1
Hodgkin lymphoma

fronts

1
Chemotherapy

drugs

5
Not mapped hereGlycopeptide antibiotic (DNA-cleaving)
Bleomycin · Blenoxane
ApprovedADC
Brentuximab vedotin · Adcetris
ApprovedCytotoxic chemotherapy (anthracycline)
Doxorubicin · Adriamycin
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
Not mapped hereVinca alkaloid (microtubule inhibitor)
Vinblastine · Velban

terms

4
De-escalation, escalation and response-adapted therapyDeauville score and PET-adapted therapyLate effects and survivorship toxicitySecondary malignancy (therapy-related cancer)